New tlr-4 antagonist aptamers

HK40137518APending Publication Date: 2026-09-11MERCK PATENT GMBH
0 Cites 0 Cited by

Patent Information

Application Number
HK62026127031
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2026-08-04
Publication Date
2026-09-11
Patent Text Reader

Abstract

It is provided an aptamer comprising the polynucleotide sequence consisting of SEQ ID NO: 7, a fragment thereof or a functionally equivalent variant thereof, comprising at least chemically modified nucleotides, with a length between 40 and 100 nucleotides and having the capability of specifically binding to TLR-4 and inhibiting TLR-4 activation. The chemically modified aptamers which derive from SEQ ID NO: 7 or its variants, have increased stability and a positive effect in breast cancer and inflammatory autoimmune neuropathy disorder such as Guillain-Barré syndrome.
Need to check novelty before this filing date? Find Prior Art